These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11366562)

  • 1. San Franscisco area: important cyclosporin study recruiting.
    James JS
    AIDS Treat News; 1999 Mar; (No 315):8. PubMed ID: 11366562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical marijuana study in San Francisco: pays $1000, 25 days in hospital.
    AIDS Treat News; 1998 Jun; (No 296):3-4. PubMed ID: 11365468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose cyclosporin: government trial recruiting, CD4 count over 500.
    AIDS Treat News; 1998 Dec; (No 308):5-6. PubMed ID: 11366076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptive/nevirapine interaction trial, New York and San Francisco.
    AIDS Treat News; 1998 Mar; (No 290):7. PubMed ID: 11365121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do women respond differently to HIV therapy than men?
    Newsline People AIDS Coalit N Y; 1998 Dec; ():31. PubMed ID: 11367087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New immune-based treatment approach: trial recruiting in San Francisco.
    James JS
    AIDS Treat News; 2001 Feb; (360):3-4. PubMed ID: 12173566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
    Stock PG; Roland ME; Carlson L; Freise CE; Roberts JP; Hirose R; Terrault NA; Frassetto LA; Palefsky JM; Tomlanovich SJ; Ascher NL
    Transplantation; 2003 Jul; 76(2):370-5. PubMed ID: 12883195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New study of Fortovase (Saquinavir) in women.
    WORLD; 1998 Nov; (No 91):4. PubMed ID: 11365973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New vaccine+HAART treatment trial enrolling at NIH. National Institutes of Health.
    James JS
    AIDS Treat News; 1998 Aug; (No 300):3-4. PubMed ID: 11365687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors.
    Jackson A; Taylor S; Boffito M
    AIDS Rev; 2004; 6(4):208-17. PubMed ID: 15700619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-20: 5-drug combination trial for heavily treated NNRTI-naive patients now recruiting.
    AIDS Treat News; 1999 Jul; (No 323):2-3. PubMed ID: 11366569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiretroviral drugs part I: PIs.
    Murphy RL
    AIDS Clin Care; 1999 May; 11(5):35-7. PubMed ID: 11367101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
    J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-378 early access program begins.
    AIDS Treat News; 1999 Oct; (No 328):1-2. PubMed ID: 11366816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.